Neil Sharma, Chief of GI at Banner MD Anderson, shared a post by Federal Research Notes, on X:
“This is where we need go to get better outcomes in pancreatic cancer.
The first iteration of new way to test:
- Early detection
- Quick test-
- High sensitivity
- Minimally invasive
Then refine to add more sensitivity and detect at earlier stages or pre-cancer.”
Quoting Federal Research Notes:
“City of Hope – led PANXEON liquid biopsy (Nature Medicine; NIH/NCI-supported) reports strong early-stage PDAC sensitivity with miRNA + CA19-9. Still investigational – needs prospective validation”
Title: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma
Authors: Caiming Xu, Alessandro Mannucci, Haiyong Han, Ruben M. Munoz, Derek Cridebring, Sourat Darabi, Yuji Toiyama, Yoshinaga Okugawa, Gagandeep Singh, Mustafa Raoof, Joon Oh Park, James Lin, Gregory Idos, Michael J. Demeure, Erkut Borazanci, Douglas B. Evans, Susan Tsai, Eunsung Jun, Carlos Becerra, Scott A. Celinski, Laleh Melstrom, Vincent Chung, Guixin Zhang, Dong Shang, David L. Bartlett, Mitsuro Kanda, Song Cheol Kim, Valsamo Anagnastou, Giulia Martina Cavestro, John S. Bolton, Ali H. Zaidi, Daniel Von Hoff, Ajay Goel
Read the full article here.
Can Pancreatic Cancer Be Detected Early? Symptoms, Biomarkers, and New Tests
